jRCT1032260439尚未招募不适用
Acceptability and Preliminary Effectiveness of an Online Nutritional Counseling Program for Patients with Type 2 Diabetes Mellitus
未提供0 个研究点目标入组 60 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 18age old over 至 76age old not(—)
- 性别
- All
入选标准
- •1.Diagnosed with type 2 diabetes mellitus and currently receiving treatment at a hospital or clinic.
- •2.Aged between 18 and 75 years at the time of informed consent.
- •3.Owns a smartphone with internet access.
- •4.Able to receive communications from study staff via SMS, LINE, or email.
- •5.Able to photograph and record all meals and beverages consumed using a smartphone.
- •6.Able to participate in scheduled online nutritional counseling sessions and study-related interviews during the study period.
- •7.Able to read, write, and communicate fluently in Japanese.
- •8.Determined by the principal investigator or sub-investigator not to have cognitive impairment.
- •9.Determined by the principal investigator or sub-investigator to be eligible for dietary fiber intervention.
- •10.Has received a full explanation of the study, sufficiently understands the study procedures, and has voluntarily provided written informed consent to participate.
排除标准
- •1.Aged 76 years or older.
- •2.Determined by a physician to be unsuitable for dietary intervention.
- •3.Has changed medication for the treatment of type 2 diabetes mellitus within the past 8 weeks.
- •4.Is currently participating in another clinical research program.
- •5.Is currently following a dietary fiber-restricted diet as directed by a physician.
- •6.Has a history of an eating disorder.
- •7.Is currently taking dietary fiber supplements.
- •8.Is subject to fluid restriction.
- •9.Has Crohn's disease, ulcerative colitis, inflammatory bowel disease, irritable bowel syndrome, or intestinal obstruction.
- •10.Has undergone intestinal surgery within the past 3 months.
- •11.Has stage 4 or higher chronic kidney disease.
- •12.Has hyperkalemia.
- •13.Is currently pregnant.
- •14.Uses a smartphone that is incompatible with MealLog, including being unable to download or effectively use the application.
- •15.Has any other condition or reason that, in the opinion of the physician, makes participation inappropriate.
研究者
相似试验
尚未招募
不适用
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on
Background Insulin (Eluminate-3)Type 2 Diabetes MellitusjRCT203126026280
招募中
不适用
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)Type 2 Diabetes MellitusjRCT2031260261165
招募中
不适用
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)Type 2 Diabetes Mellitus and Impaired Renal FunctionjRCT2031260268118
尚未招募
不适用
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)Renal Insufficiency, ChronicjRCT2031260364200
招募中
不适用
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)Type 2 Diabetes MellitusjRCT203126027880
